SOFINNOVA-PARTNERS
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Andrew M. Weiss, an experienced leader in the medical devices industry whose ties to Sofinnova stretch back 20 years, as Venture Partner.
Mr. Weiss, who is based in San Francisco, will investigate global medical device investment opportunities across the Sofinnova Partners platform of strategies. He is currently an independent member on the boards of May Health and SafeHeal, two Sofinnova portfolio companies.
In 2013, Mr. Weiss was brought in as CEO to lead ReCor Medical, a company founded in 2009 by Mano Iyer, then an entrepreneur in residence at Sofinnova and now a partner in the Sofinnova medtech acceleration team. Mr. Weiss led ReCor, a pioneer in the use of ultrasound renal denervation to treat hypertension, as it scaled up to 175 employees, went through its clinical trials and was purchased by Otsuka Medical Devices in 2018. He also led preparations for ReCor’s US FDA PMA Approval, achieved in November of this year. Sofinnova Partners was the sole VC investor in ReCor at the time of the sale. Mr. Weiss retired from ReCor/Otsuka Medical Devices in April of 2023.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “It's fantastic to have Andy back working with Sofinnova Partners. He is an outstanding leader with impeccable credentials in the medical devices sector. His performance at ReCor, a pioneering company, is legendary."
Mr. Weiss said: “I share Sofinnova’s passion for finding, nurturing and bringing new medical device therapies to patients. Having worked both informally and as a portfolio company CEO with Sofinnova for the past 20 years, I know that they have the best team, and are the gold-standard medical device venture group on a global basis. I am honored to become part of this team.”
Before he took the reins at ReCor, Mr. Weiss held leadership roles including President & CEO of Vital Images (acquired by Toshiba), VP & General Manager of the Medtronic Surgical Navigation Systems and Neurological Businesses, and President & CEO of CoAxia, which was sold to Zoll Medical.
Mr. Weiss is a graduate of the Massachusetts Institute of Technology with a degree in mechanical engineering and has an MBA from the Columbia University Graduate School of Business.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231221098742/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“All Genetic Diseases Could be Cured within a Decade”, Hears Dubai Future Forum20.11.2025 14:15:00 CET | Press release
All known genetic diseases could be cured within the next decade thanks to major advances in gene editing, a leading scientist told the Dubai Future Forum 2025. Discussing his company’s research, Dr. Trevor Martin, Co-founder and CEO of Mammoth Biosciences, described “a one-time cure that will reshape the healthcare system as we know it.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120548681/en/ Dubai Future Forum 2025 (Photo: AETOSWire) Opening the forum, Khalfan Belhoul, CEO of Dubai Future Foundation, introduced the concept of “national cognitive potential”, arguing that countries in the future will gain a competitive edge in fields like AI by leveraging the collective cognitive strength of their societies. In another session, Dr. Nikku Madhusudhan, Professor of Astrophysics at the University of Cambridge, said there is a “good chance” humanity will discover life on another planet—possibly in the next decade. He exp
12 Major Verification Trends in 2026: Regula on the Birth of a New Digital Identity20.11.2025 14:00:00 CET | Press release
How we verify is changing — and so is who and what we verify. Are we dealing with real people, fraudsters, or machines acting on their behalf? A new Regula report on 12 identity verification trendsexamines how these shifts are forcing businesses to rebuild their verification processes to stay ahead of fraud, comply with regulations, and regain eroding customer confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120373343/en/ Identity is leaving the human domain: Regula’s forecast illustrates the emerging need to verify systems, autonomous agents, and machine customers. The new face of fraud The identity threat landscape has entered a new industrial phase, defined by three structural shifts: Machine identity. Identity verification (IDV) is no longer limited to people. It now extends to autonomous systems acting on their behalf — AI agents that can open accounts, submit documents, and bypass checks on their own. Frau
Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies20.11.2025 14:00:00 CET | Press release
AI-driven genomic foundation model integrates wet-lab validation, population-scale genomics, and advanced machine learning to improve gene editing design at scale Founding team unites CRISPR pioneers and AI leaders, supported by a world-class Scientific Advisory Board including Dr. Vic Myer (former CTO, Editas Medicine) and Dr. Saar Gill (UPenn) Cassidy Bio, a biotechnology company developing the first AI-driven genomic foundation model to enhance the design of gene editing therapies, today announced its launch and the closing of an $8 million seed financing round. The company will use the funding to advance its platform, built as a holistic solution designed to bring precision, speed, and clinical confidence to the rapidly growing field of gene therapies. Cassidy Bio’s AI-driven genomic foundation model combines proprietary wet-lab data, population-scale genomic insights, and advanced machine learning to predict the best pairings of guides, enzymes, and delivery modalities, matching t
Scientist.com Completes Acquisition by GHO Capital Partners to Accelerate Global R&D Orchestration20.11.2025 13:55:00 CET | Press release
Strategic partnership finalized, unlocking expanded AI-driven platform capabilities and international growth Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform, and GHO Capital Partners LLP (“GHO”), the specialist private equity investor in global healthcare, today announced the successful closing of GHO’s acquisition of Scientist.com. The transaction marks the beginning of an accelerated expansion phase, strengthening Scientist.com’s mission to transform pharmaceutical R&D by streamlining the entire outsourced research lifecycle. “This is a pivotal moment for Scientist.com and for the global research community we support,” said Kevin Lustig, CEO and Chris Petersen, CTO, the founders of Scientist.com. “Partnering with GHO, a team that shares our vision and brings deep expertise in scaling healthcare technology companies, enables us to invest aggressively in our AI-powered orchestration platform and expand our global footprint. Together, we are bet
SimpliStor™ Solid State Data Recorder Delivers High-Speed, Radiation-Tolerant Storage for Next-Generation Space Missions20.11.2025 13:00:00 CET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the SimpliStor™ Solid State Data Recorder (SSDR), a next-generation, radiation-tolerant data recorder that gives satellite operators, system integrators, and spacecraft designers a faster, smarter, and more resilient way to capture and protect mission-critical information in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120514203/en/ Frontgrade's SimpiStor™ 2.5TB Solid-State Data Recorder High-Throughput Performance SimpliStor delivers 2.5 terabytes of storage and 10Gbps throughput in a compact 3U SpaceVPX package, combining exceptional performance with low power consumption. Users can record more data in less time, with latency under 100 microseconds and continuous “store-to-full” recording, ensuring no data loss during peak operations. A 33-minute continuo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom